Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of continued Iressa plus chemotherapy versus chemotherapy alone in EGFR-mutant NSCLC after progression on first-line Iressa
2011-004942-16Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Iressa plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoint: Progression-free survival. Started Dec 2011; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-004942-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004942-16.